Nanobiotix (NBTX)

Currency in USD
27.90
-3.26(-10.46%)
Closed·
27.900.00(0.00%)
·
Advertisement
NBTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
27.2830.36
52 wk Range
14.7857.14
Key Statistics
Prev. Close
31.16
Open
29.99
Day's Range
27.28-30.36
52 wk Range
14.78-57.14
Volume
192.39K
Average Volume (3m)
145.56K
1-Year Change
48.8794%
Book Value / Share
-0.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NBTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
54.41
Upside
+95.01%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Nanobiotix News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 54.41
(+95.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy64.00+129.39%-New Coverage15/09/2026
Leerink
Buy46.00+64.87%37.00Maintain04/06/2026
UBS
Hold30.00+7.53%3.50Maintain01/05/2026
Guggenheim
Buy36.00+29.03%26.00Maintain02/04/2026
Leerink Partners
Buy37.00+32.62%26.00Maintain01/04/2026

Nanobiotix Earnings Call Summary for H2/2025

  • Nanobiotix cut FY 2025 net loss to €24M from €68.1M, aided by amended J&J licensing deal and 43% R&D expense reduction
  • Company missed EPS forecast at -0.5069 vs -0.3943 expected; revenue reached €32.6M driven by one-time accounting impact
  • Stock rose 3.47% to $31.94 in premarket despite EPS miss; shares gained 762% over past year with $1.49B market cap
  • Cash position of €52.8M extends runway into early 2028; projects EPS of -0.34 for FY2025 and -0.24 for FY2026
  • Strategic focus on NBTXR3 oncology product and capital-efficient development; anticipates milestone payments from Janssen partnership
Last Updated: 01/04/2026, 14:20
Read Full Transcript

Earnings

Latest Release
24/09/2026
EPS / Forecast
-0.29 / -0.29
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare NBTX to Peers and Sector

Metrics to compare
NBTX
Peers
Sector
Relationship
P/E Ratio
−24.4x−2.5x−0.3x
PEG Ratio
18.34−0.030.00
Price/Book
−38.7x0.9x2.6x
Price / LTM Sales
112.2x7.8x3.0x
Upside (Analyst Target)
74.7%290.0%56.4%
Fair Value Upside
Unlock13.0%7.2%Unlock

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.03M7.94%125.68M
Other Institutional Investors
21.69M42.68%675.77M
Public Companies & Retail Investors
25.09M49.38%781.84M
Total
50.81M100.00%1.58B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Johnson & Johnson Innovation - JJDC, Inc.11.07%5,623,816175,238
Artal Group S.A.8.82%4,483,275139,699

People Also Watch

66.62
JBSS
+0.17%
12.01
RCEL
+2.39%
25.40
NANOB
-7.97%
24.77
XNCR
-0.72%
21.01
TYRA
-3.93%

FAQ

What Is the Nanobiotix (NASDAQ: NBTX) Share Price Today?

The Nanobiotix stock price today is 27.90 USD.

What Stock Exchange Does Nanobiotix (NBTX) Trade On?

Nanobiotix is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Nanobiotix?

The stock symbol (also called a 'ticker') for Nanobiotix is "NBTX."

What Is the Current Nanobiotix Market Capitalisation?

As of today, Nanobiotix (NASDAQ: NBTX) market cap is 1.45B USD.

What Is Nanobiotix's (NBTX) Earnings Per Share (TTM)?

The Nanobiotix EPS is currently -1.11 (Trailing Twelve Months).

When Is the Next Nanobiotix Earnings Date?

Nanobiotix's next earnings report will be released on 17/11/2026.

Is NBTX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Nanobiotix moving averages and other technical indicators, the daily buy/sell signal for NBTX stock is Strong Sell.

How Many Times Has Nanobiotix Stock Split?

Nanobiotix has split 0 times. (See the NBTX stock split history page for full effective split date and price information.)

How Many Employees Does Nanobiotix Have?

Nanobiotix has 100 employees, based on their latest Companies House report.

What is the current trading status of Nanobiotix (NASDAQ: NBTX)?

As of 01/10/2026, Nanobiotix (NBTX) is trading at a share price of 27.90 USD, with a previous close of 31.16 USD. The stock has fluctuated within a day range of 27.28 USD to 30.36 USD, while its 52-week range spans from 14.78 USD to 57.14 USD.

What Is Nanobiotix (NBTX) Price Target According to Analysts?

The average 12-month price target for Nanobiotix is 54.41 USD, with a high estimate of 69.69889065 USD and a low estimate of 29.79963776 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +95.01% Upside potential.

What Is the NBTX Premarket Price?

NBTX's last pre-market stock price is 29.99 USD. The pre-market share volume is 1,490.00, and the stock has decreased by -1.17, or -3.75%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.